{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:34:24Z","timestamp":1793421264404,"version":"4.5.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030076, 82070161, 81970151, 81670162 and 81870134"],"award-info":[{"award-number":["82030076, 82070161, 81970151, 81670162 and 81870134"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017380","name":"Science and Technology Foundation of Shenzhen City","doi-asserted-by":"publisher","award":["JCYJ20190808163601776, JCYJ20200109113810154"],"award-info":[{"award-number":["JCYJ20190808163601776, JCYJ20200109113810154"]}],"id":[{"id":"10.13039\/100017380","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017621","name":"Shenzhen Key Laboratory Fund","doi-asserted-by":"publisher","award":["ZDSYS20200811143757022"],"award-info":[{"award-number":["ZDSYS20200811143757022"]}],"id":[{"id":"10.13039\/501100017621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZSM202111004"],"award-info":[{"award-number":["SZSM202111004"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Pancreatic cancer (PC) is one of the most malignant tumors in digestive system due to its highly invasive and metastatic properties. At present, conventional treatment strategies for PC show the limited clinical efficacy. Therefore, novel effective therapeutic strategies are urgently needed. Here, we report a case of complete remission of advanced PC induced by claudin18.2-targeted CAR-T cell therapy. The patient was a 72-year-old man who was diagnosed with pancreatic ductal adenocarcinoma 2 years ago, and he experienced tumor recurrence and multiple metastases after pancreaticoduodenectomy and multi-line chemotherapies, including liver, peritoneum, and cervical lymph node metastases. Then, the patient was referred to our department for further treatment of metastatic PC, and he was enrolled in a clinical trial of claudin18.2-targeted CAR-T cell therapy. After lymphodepleting chemotherapy, the patient received claudin18.2-targeted CAR-T cell infusion at a dose of 1.2\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    cells\/kg on November 21, 2022. During CAR-T cell therapy, the patient experienced grade 2 cytokine release syndrome (CRS) and gastric mucosa injury, which were controlled by tocilizumab and conventional symptomatic and supportive treatment. The patient achieved a complete response (CR) 1 month after claudin18.2-targeted CAR-T cell therapy, and remained in clinical remission for 8 months. Unfortunately, the patient experienced claudin18.2-negative relapse in July, 2023. Despite antigen-negative relapse after claudin18.2-targeted CAR-T cell infusion, the patient achieved sustained remission for 8 months, which indicates that claudin18.2-targeted CAR-T cell therapy is an extremely effective therapeutic strategy for the treatment of advanced PC.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2024.1325860","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T23:32:08Z","timestamp":1709163128000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Guocheng","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bochen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqiao","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09515","article-title":"Distant metastasis occurs late during the genetic evolution of pancreatic cancer","volume":"467","author":"Yachida","year":"2010","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.236","article-title":"Advanced pancreatic carcinoma: current treatment and future challenges","volume":"7","author":"Stathis","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-017-0473-4","article-title":"Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer","volume":"10","author":"Singh","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v14.i7.1252","article-title":"Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma","volume":"14","author":"Wang","year":"2022","journal-title":"World J Gastrointest Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28400","article-title":"Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms","volume":"134","author":"W\u00f6ll","year":"2014","journal-title":"Int J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy","volume":"10","author":"Cao","year":"2022","journal-title":"biomark Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-023-01491-9","article-title":"CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer","volume":"16","author":"Qi","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.14670\/HH-18-477","article-title":"Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients","volume":"37","author":"Zhang","year":"2022","journal-title":"Histol Histopathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.pan.2020.02.006","article-title":"Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma","volume":"20","author":"Cutmore","year":"2020","journal-title":"Pancreatology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030601","article-title":"Tumor Growth Suppression of Pancreatic Cancer Orthotopic Xenograft Model by CEA-Targeting CAR-T Cells","volume":"15","author":"Sato","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-023-01467-9","article-title":"GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer","volume":"16","author":"Fan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101803","article-title":"Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models","volume":"39","author":"Yuan","year":"2024","journal-title":"Transl Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cells8091070","article-title":"Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma","volume":"8","author":"Yazdanifar","year":"2019","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04017-x","article-title":"CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer","volume":"148","author":"Zhu","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-017-4027-2","article-title":"Prognostic Scoring System for Patients Who Present with a Gastric Outlet Obstruction Caused by Advanced Pancreatic Adenocarcinoma","volume":"41","author":"Sugiura","year":"2017","journal-title":"World J Surg"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/or.2013.2556","article-title":"A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients","volume":"30","author":"Yutani","year":"2013","journal-title":"Oncol Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1325860\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T23:32:12Z","timestamp":1709163132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1325860\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2024.1325860"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1325860","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"article-number":"1325860"}}